PDF DatasheetHuman Anti-EGFR (Epidermal Growth Factor Receptor) Antibody Product Attributes
EGFR (Epidermal Growth Factor Receptor) Previously Observed Antibody Staining Patterns
Observed Subcellular, Organelle Specific Staining Data:
Anti-EGFR antibody staining is expected to be primarily localized to the plasma membrane.
Observed Antibody Staining Data By Tissue Type:
Variations in EGFR antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. An intense signal was observed in trophoblastic cells in the placenta. More moderate antibody staining intensity was present in trophoblastic cells in the placenta. Low, but measureable presence of EGFR could be seen inhepatocytes in liver, Leydig cells in the testis, melanocytes in skin, myocytes in skeletal muscle, squamous epithelial cells in the tonsil and vagina and urothelial cells in the urinary bladder. We were unable to detect EGFR in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of EGFR expression as measured by anti-EGFR antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | – | – | – | – | – | + | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| EGFR Variability | + | + | + | + | + | ++ | + | ++ | + | + | + | + | + | + | + | + | + | + | + | + |
| EGFR (Epidermal Growth Factor Receptor) General Information | |
|---|---|
| Alternate Names | |
| Erbb1; ERBB1; Errp; HER1; mENA; PIG61; Proto-oncogene c-ErbB-1; Receptor Tyrosine Protein Kinase; ErbB1; Urogastrone; wa2; Wa5 | |
| Molecular Weight | |
| ~170kDa (wild type) and ~145kDa (vIII variant) | |
| Chromosomal Location | |
| Ships on blue ice. | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | 1956 |
| Entrez Gene ID | EGFR |
| UniProt ID(s) | P00533 |
| UniGene ID(s) | Hs488293 |
| COSMIC ID Link(s) | EGFR |
| KEGG Gene ID(s) | hsa:1956 |
| General Description of EGFR (Epidermal Growth Factor Receptor). | |
| This MAb recognizes a protein of 170kDa, identified as EGFR. EGFR is type I receptor tyrosine kinase with sequence homology to erbB-1, -2, -3 -4 or HER-1, -2, -3 -4. It binds to Epidermal Growth Factor (EGF), Transforming Growth Factor-a (TGF-a), Heparin-binding EGF (HB-EGF), amphiregulin, betacellulin and epiregulin. EGFR is overexpressed in tumors of breast, brain, bladder, lung, gastric, head & neck, esophagus, cervix, vulva, ovary, and endometrium. It is predominantly present in squamous cell carcinomas. | |
There are no reviews yet.